DOI QR코드

DOI QR Code

Regulatory Mechanisms of Annexin-Induced Chemotherapy Resistance in Cisplatin Resistant Lung Adenocarcinoma

  • Wang, Chao (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Xiao, Qian (Department of Dermatology, Xijing Hospital, Fourth Military Medical University) ;
  • Li, Yu-Wen (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Zhao, Chao (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Jia, Na (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Li, Rui-Li (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Cao, Shan-Shan (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Cui, Jia (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Wang, Lu (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Wu, Yin (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Wen, Ai-Dong (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University)
  • Published : 2014.04.01

Abstract

Adenocarcinoma of lung has high incidence and a poor prognosis, woith chemotherapy as the main therapeutic tool, most commonly with cisplatin. However, chemotherapy resistance develops in the majority of patients during clinic treatment. Mechanisms of resistance are complex and still unclear. Although annexin play important roles in various tumor resistance mechanisms, their actions in cisplatin-resistant lung adenocarcinoma remain unclear. Preliminary studies by our group found that in cisplatin-resistant lung cancer A549 cells and lung adenocarcinoma tissues, both mRNA and protein expression of annexins A1, A2 and A3 is increased. Using a library of annexin A1, A2 and A3 targeting combined molecules already established by ourselves we found that specific targeting decreased cisplatin-resistance. Taken together, the underlined effects of annexins A1, A2 and A3 on drug resistance and suggest molecular mechanisms in cisplatin-resistant A549 cells both in vivo and in vitro. Furthermore, the study points to improved research on occurrence and development of lung adenocarcinoma, with provision of effective targets and programmes for lung adenocarcinoma therapy in the clinic.

Keywords

Annexin;lung adenocarcinoma;chemotherapy;effective targets

Acknowledgement

Supported by : National Natural Science Foundation of China

References

  1. Yan X, Yin J, Yao H, et al (2010). Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res, 70, 1616-24. https://doi.org/10.1158/0008-5472.CAN-09-3215
  2. Yee DS, Narula N, Ramzy I, et al (2007). Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med, 131, 902-8.
  3. Yu G, Wang J, Chen Y, et al (2008). Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis, 25, 695-702. https://doi.org/10.1007/s10585-008-9178-y
  4. Zhang MC, Hu CP (2006). Lung cancer molecular mechanisms of cisplatin resistance. Int J Respiration, 2, 152-5.
  5. Zhou YM, Liu J, Sun W (2014). MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev, 15, 1391-6. https://doi.org/10.7314/APJCP.2014.15.3.1391
  6. Sharma MR, Koltowski L, Ownbey RT, et al (2006). Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol, 81, 146-56. https://doi.org/10.1016/j.yexmp.2006.03.003
  7. Langer CJ, Besse B, Gualberto A, et al (2010). The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol, 28, 5311-20. https://doi.org/10.1200/JCO.2010.28.8126
  8. Mussunoor S, Murray GI (2008). The role of annexins in tumour development and progression. J Pathol, 216, 131-40. https://doi.org/10.1002/path.2400
  9. Protzel C, Richter M, Poetsch M, et al (2011). The role of annexins I, II and IV in tumor development, progression and metastasis of human penile squamous cell carcinomas. World J Urol, 29, 393-8. https://doi.org/10.1007/s00345-010-0575-x
  10. Stewart DJ, Chiritescu G, Dahrouge S, et al (2007). Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev, 33, 101-37. https://doi.org/10.1016/j.ctrv.2006.12.002
  11. Stewart DJ (2010). Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol, 75, 173-234. https://doi.org/10.1016/j.critrevonc.2009.11.006
  12. Sun DS, Hu LK, Cai Y, et al (2014). A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1233-9. https://doi.org/10.7314/APJCP.2014.15.3.1233
  13. Wang LP, Bi J, Yao C, et al (2010). Annexin A1 expression and its prognostic significance in human breast cancer. Neoplasma, 57, 253-9. https://doi.org/10.4149/neo_2010_03_253
  14. Wang H, Gui SY, Chen FH, et al (2013). New insights into 4-amino-2-tri-fluoromethyl-phenyl ester inhibition of cell growth and migration in the A549 lung adenocarcinoma cell line. Asian Pac J Cancer Prev, 14, 7265-70. https://doi.org/10.7314/APJCP.2013.14.12.7265
  15. Fatimathas L, Moss SE (2010). Annexins as disease modifiers. Histol Histopathol, 25, 527-32.
  16. Emoto K, Sawada H, Yamada Y, et al (2001). Annexin II over-expression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res, 21, 1339-45.
  17. Esposito I, Penzel R, Chaib-Harrireche M, et al (2006). Tenascin C and annexin 2 expression in the process of pancreatic carcinogenesis. J Pathol, 208, 673-85. https://doi.org/10.1002/path.1935
  18. Fan Jiang, Jiang Ge-nin (2008). Advances in treatment of non-small cell lung cancer. Chinese J Clin, 2, 11-4.
  19. Cao Y, Li Y, Edelweiss M, et al (2008). Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol, 16, 530-4. https://doi.org/10.1097/PAI.0b013e31817432c3
  20. Chen CY, Shen JQ, Wang F, et al (2012). Prognostic Significance of Annexin A1 Expression in Pancreatic Ductal Adenocarcinoma. Asian Pac J Cancer Prev, 13, 4707-12. https://doi.org/10.7314/APJCP.2012.13.9.4707
  21. Gerke V, Creutz CE, Moss SE (2005). Annexins: linking $Ca^{2+}$ signalling to membrane dynamics. Nat Rev Mol Cell Biol, 6, 449-61. https://doi.org/10.1038/nrm1661
  22. Gillette JM, Chan DC, Nielsen-Preiss SM (2004). Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem, 92, 820-32. https://doi.org/10.1002/jcb.20117
  23. Huang Y, Jin Y, Yan CH, et al (2008). Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem, 309, 117-23. https://doi.org/10.1007/s11010-007-9649-5

Cited by

  1. Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice vol.8, pp.4, 2014, https://doi.org/10.3892/ol.2014.2379
  2. Tumor Growth of Lung Cancer Cells vol.35, pp.10, 2016, https://doi.org/10.1089/dna.2016.3360
  3. Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis vol.13, pp.1, 2015, https://doi.org/10.1186/s12916-015-0392-6